Izotropic announces $300,000 private placement for working capital

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced plans for a non-brokered private placement to raise up to $300,000 for general working capital.

The medical device company plans to issue 1.2 million units at $0.25 each. Each unit consists of one common share and one transferable warrant, with warrants exercisable at $0.25 per share for three years from closing.

Izotropic develops imaging-based products for breast cancer screening, diagnosis and treatment. The company said its primary objective remains securing capital financing to fund commercialization of its IzoView Breast CT system while evaluating non-dilutive funding options.

The company reported it continues evaluating strategic relationships that have advanced to due diligence stages. These potential arrangements may include global business units, territory and manufacturing rights, master distribution agreements, and accelerated regulatory procedures in additional markets.

Securities issued in the offering will be subject to a four-month-and-one-day statutory hold period from issuance date. The offering requires regulatory approvals before completion.

The company noted the securities will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or applicable exemption.

Izotropic said it presented its business plan and seven-year financial model to potential partners, covering regulatory strategies, go-to-market planning, distribution models, revenue streams, and risk mitigation strategies. Board members and advisory board participants are leading these presentations.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Gamma Resources raises private placement ceiling to $1.75M
• Target (TGT) files mixed shelf